EUSA Pharma hopes IL-6 drug will succeed in COVID-19 where rivals failedUK-based EUSA Pharma has begun a late-stage trial of its antibody siltuximab in COVID-19, hoping that the IL-6 Share XEUSA Pharma hopes IL-6 drug will succeed in COVID-19 where rivals failedhttps://pharmaphorum.com/news/eusa-pharma-hopes-il-6-drug-will-work-in-covid-19-where-class-rivals-failed/
Sanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polypsSanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps Share XSanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polypshttps://pharmaphorum.com/news/dupixent-on-notice-as-fda-reviews-gsks-nucala-for-nasal-polyps/
Regeneron’s COVID-19 antibody cocktail therapy hits safety problemRegeneron’s coronavirus antibody cocktail therapy against COVID-19, famously used to treat president Donald Trump, has hit a safety Share XRegeneron’s COVID-19 antibody cocktail therapy hits safety problemhttps://pharmaphorum.com/news/regenerons-covid-19-antibody-cocktail-therapy-hits-safety-problem/
FDA sets Feb decision date for Libtayo lung cancer challenge to KeytrudaThe FDA has started a priority review of Regeneron and Sanofi’s checkpoint inhibitor Libtayo in first-line non-small cell Share XFDA sets Feb decision date for Libtayo lung cancer challenge to Keytrudahttps://pharmaphorum.com/news/fda-sets-feb-decision-date-for-libtayos-lung-cancer-challenge-to-keytruda/
Regeneron’s antibody cocktail approved by FDA for EbolaAn antibody cocktail from Regeneron has been approved by the FDA as the first treatment for Ebola, offering Share XRegeneron’s antibody cocktail approved by FDA for Ebolahttps://pharmaphorum.com/news/regenerons-antibody-cocktail-approved-by-fda-for-ebola/
Lilly pauses COVID-19 antibody trial after factory hits trouble with FDAEli Lilly has put a clinical trial of its COVID-19 antibody therapy on hold after FDA inspectors found Share XLilly pauses COVID-19 antibody trial after factory hits trouble with FDAhttps://pharmaphorum.com/news/lilly-pauses-covid-19-antibody-trial-after-factory-hits-trouble-with-fda/
Spotlight on COVID-19 antibody therapies after Trump’s recoveryThe spotlight remains on the potential of antibody therapies as a possible way out of the COVID-19 pandemic Share XSpotlight on COVID-19 antibody therapies after Trump’s recoveryhttps://pharmaphorum.com/news/spotlight-on-covid-19-antibody-therapies-after-trumps-recovery/
Regeneron joins Lilly in seeking emergency OK for COVID-19 antibodyRegeneron has followed Eli Lilly in asking the FDA for emergency approval of its COVID-19 antibody therapy, shortly Share XRegeneron joins Lilly in seeking emergency OK for COVID-19 antibodyhttps://pharmaphorum.com/news/regeneron-joins-lilly-in-seeking-emergency-ok-for-covid-19-antibody/
Lilly asks FDA for emergency clearance for COVID-19 antibody therapyEli Lilly has asked the FDA for an Emergency Use Authorization for its COVID-19 antibody therapy, after announcing Share XLilly asks FDA for emergency clearance for COVID-19 antibody therapyhttps://pharmaphorum.com/news/lilly-asks-fda-for-emergency-clearance-for-covid-19-antibody-therapy/
